

Allschwil, Switzerland, July 28, 2020

## **Polyphor strengthens financial flexibility with CHF 19.3 million equity-linked financing**

Polyphor AG (SIX: POLN) today announced that it has entered into an equity-linked financing arrangement with the French company IRIS to raise a gross amount of up to CHF 19.3 million over the period of two years. IRIS will receive Polyphor shares to be created from the Company's conditional capital based on this interest-free mandatory convertible bonds program. It remains at the sole discretion of Polyphor to suspend or terminate the staggered financing.

"We are encouraged by the progress we have made in implementing Polyphor's renewed strategy to advance our pipeline in oncology and novel antibiotics. In particular, the study progress with our phase III asset balixafortide continues with 335 patients randomized to date despite the challenges provided by COVID-19. We believe that balixafortide has the potential to become a major breakthrough in treatment of metastatic breast cancer patients," says Gokhan Batur, CEO of Polyphor. "The flexibility of the planned financing instrument allows us to ensure the continuity of its development in breast cancer, which is a key strategic imperative for us, as well as to explore its potential in other cancer indications."

IRIS is committed to buy on a monthly basis over a period of two years twenty-four tranches of CHF 800,000 of unsecured zero-coupon mandatory convertible bonds. The program can be tailor-made in terms of period and tranche size, according to Polyphor's financing needs. During the term of the financing, IRIS will convert each month the mandatory convertible bonds into shares at a discount to the applicable volume weighted average price (VWAP). These shares are expected to be sold on the market or in block trades.

***For further information please contact:******For Investors:***

Hernan Levett  
Chief Financial Officer  
Polyphor Ltd.  
Tel: +41 61 567 16 00  
Email: [IR@polyphor.com](mailto:IR@polyphor.com)

***For Media:***

Stephan Feldhaus  
Feldhaus & Partner GmbH  
Tel: +41 79 865 92 56  
Email: [feldhaus@feldhaus-partner.ch](mailto:feldhaus@feldhaus-partner.ch)

**About Polyphor**

Polyphor is a research-driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing first-in-class molecules in oncology and antimicrobial resistance leveraging the company's leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company's lead OMPTA program is an inhaled formulation of murepavadin for the treatment of *Pseudomonas aeruginosa* infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit [www.polyphor.com](http://www.polyphor.com).

**Disclaimer**

This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor's results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.